| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 03/16/2006 | CA2577408A1 Use of (halobenzyloxy) benzylamino-propanamides for the manufacture of medicaments active as sodium and/or calcium channel selective modulators |
| 03/16/2006 | CA2576393A1 Novel derivatives of 3,5-seco-4-norcholestane and use thereof |
| 03/16/2006 | CA2575751A1 8-(3-amino-piperidin-1-yl)-7-(but-2-inyl)-xanthines, production thereof and use thereof as medicaments |
| 03/16/2006 | CA2571360A1 Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines useful in inducing cytokine biosynthesis in animals |
| 03/16/2006 | CA2565235A1 [3.2.0] heterocyclic compounds and methods of using the same |
| 03/16/2006 | CA2519418A1 New injectable formulations containing progesterone |
| 03/15/2006 | EP1634951A1 Novel protein |
| 03/15/2006 | EP1634892A2 Composition and methods for the diagnosis of tumours |
| 03/15/2006 | EP1634888A2 Synthesis of 2'-deoxy-L-nucleosides |
| 03/15/2006 | EP1634883A1 2-substituted phenyl-5,7-dialkyl-3,7-dihydropyrrole[2,3-d]pyrimidine-4-one derivatives, the preparation and the pharmaceutical use thereof |
| 03/15/2006 | EP1634880A2 Processes for preparing losartan and losartan potassium |
| 03/15/2006 | EP1634877A1 Mixture and compounds from mycelia of antrodia camphorata and use thereof |
| 03/15/2006 | EP1634876A2 Heterocyclic compounds for the treatment of hyperlipidemia agents |
| 03/15/2006 | EP1634874A1 Imidazolidine derivative |
| 03/15/2006 | EP1634873A1 Sigma receptor inhibitors |
| 03/15/2006 | EP1634872A1 Pyrazole derivatives as sigma receptor inhibitors |
| 03/15/2006 | EP1634870A1 Process and intermediates for the selective synthesis of Fluvastatin |
| 03/15/2006 | EP1634865A1 Sertraline hydrochloride polymorphs |
| 03/15/2006 | EP1634618A1 Method for identifying compounds that increase bone mineral density |
| 03/15/2006 | EP1634607A2 Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents |
| 03/15/2006 | EP1634606A1 Drug for airway administration |
| 03/15/2006 | EP1634601A2 Dietary supplement comprising soyabean, mushroom and mung bean |
| 03/15/2006 | EP1634599A1 Iimmune stimulatory infant nutrition |
| 03/15/2006 | EP1634598A1 Use of piperazine derivatives and analogues for the manufacture of a medicament for the prophylaxis and/or treatment of disorders of food ingestion |
| 03/15/2006 | EP1634597A1 Compositions comprising dextromethorphan and quinidine or quinine for the treatment of emotional lability |
| 03/15/2006 | EP1634596A1 Aporphine and oxoaporphine and the medical use thereof |
| 03/15/2006 | EP1634595A1 N-Phenylbenzamide derivatives as drugs for the treatment of Chronic Obstructive Pulmonary Disease (COPD) |
| 03/15/2006 | EP1634594A1 Use of 3-substituted oxindole derivatives as KCNQ potassium channel modulators |
| 03/15/2006 | EP1634593A2 Hypoglycemics comprising organic zinc (II) complexes |
| 03/15/2006 | EP1634592A2 Hypoglycemics comprising organic zinc (II) complexes |
| 03/15/2006 | EP1634591A2 Hypoglycemics comprising organic zinc (II) complexes |
| 03/15/2006 | EP1634590A1 Coronavirus inactivating agent |
| 03/15/2006 | EP1634589A1 Aqueous olanexidine solution, method of preparing the same, and disinfectant |
| 03/15/2006 | EP1634588A1 Compositions and foods and drinks contiaing higher fatty acid derivative |
| 03/15/2006 | EP1634586A1 Fast water-dispersible domperidone tablets |
| 03/15/2006 | EP1634585A1 Drug-containing sustained release microparticle, process for producing the same and preparation containing the microparticle |
| 03/15/2006 | EP1634583A1 Testosterone gels comprising propylene glycol as penetration enhancer |
| 03/15/2006 | EP1634499A1 Aqueous compositions for disinfection and/or sterilization |
| 03/15/2006 | EP1634498A2 Exo-S-mecamylamine formulation |
| 03/15/2006 | EP1634079A1 Screening method for substances binding to merozoite surface protein-1/42 |
| 03/15/2006 | EP1634025A1 Process for increasing liquid extraction from fabrics |
| 03/15/2006 | EP1633885A2 Methods for predicting drug efficacy in patients afflicted with hypertension |
| 03/15/2006 | EP1633872A2 Novel human protease inhibitor-like proteins and polynucleotides encoding the same |
| 03/15/2006 | EP1633871A1 Double-stranded nucleic acid |
| 03/15/2006 | EP1633853A2 Severe acute respiratory syndrome dna vaccine compositions and methods of use |
| 03/15/2006 | EP1633770A2 Double-stranded ribonucleic acid with increased effectiveness in an organism |
| 03/15/2006 | EP1633765A1 Novel 14 and 15 membered-ring compounds |
| 03/15/2006 | EP1633764A1 Q-alkyl macrolide and azalide derivatives and regioselective process for their preparation |
| 03/15/2006 | EP1633756A2 A2a adenosine receptor antagonists |
| 03/15/2006 | EP1633753A1 Novel crystalline forms of valacyclovir hydrochloride |
| 03/15/2006 | EP1633749A2 Deazaflavin compounds and methods of use thereof |
| 03/15/2006 | EP1633746A1 New indole derivatives as factor xa inhibitors |
| 03/15/2006 | EP1633743A1 Cyclic amine derivatives and their use in the treatment of inflammation-related disorders mediated by bradykinin |
| 03/15/2006 | EP1633740A2 Chemical compounds |
| 03/15/2006 | EP1633736A1 Barium salt of benzimidazole derivative |
| 03/15/2006 | EP1633735A1 Derivatives of piperidinyl- and piperazinyl-alkyl carbamates, preparation methods thereof and application of same in therapeutics |
| 03/15/2006 | EP1633734A2 Mucin synthesis inhibitors |
| 03/15/2006 | EP1633733A1 Cannabinoid derivatives, methods of making, and use thereof |
| 03/15/2006 | EP1633732A1 Benzyl sulfonamide derivatives as androgen receptor antagonists |
| 03/15/2006 | EP1633725A1 Hepatitis c virus inhibitors |
| 03/15/2006 | EP1633724A1 Phthalazinone derivatives |
| 03/15/2006 | EP1633721A1 Process for the preparation of nonpeptide substituted spirobenzoazepine derivatives |
| 03/15/2006 | EP1633718A2 COMPOSITIONS AND METHODS FOR INHIBITING TGF-s |
| 03/15/2006 | EP1633717A1 New p2x7 receptor antagonists and their use |
| 03/15/2006 | EP1633716A2 Biarylmethyl indolines, indoles and tetrahydroquinolines, useful as serine protease inhibitors |
| 03/15/2006 | EP1633715A1 2-(6-amino-pyridin-3-yl)-2-hydroxyethylamine derivatives as beta 2-adrenoceptors agonists |
| 03/15/2006 | EP1633714A1 2-amino-pyridine derivatives as beta-2 adrenoreceptor agonists |
| 03/15/2006 | EP1633712A2 Six membered amino-amide derivatives as angiogenesis inhibitors |
| 03/15/2006 | EP1633710A1 Isoindolin-1-one compounds as kinase inhibitors |
| 03/15/2006 | EP1633707A1 1- (alkylaminoalkyl-pyrolidin-/piperidinyl) -2, 2-diphenylacetamide derivatives as muscarinic receptor antagonists |
| 03/15/2006 | EP1633696A1 Immunomodulation with novel pharmaceutical compositions |
| 03/15/2006 | EP1633695A2 Smooth muscle spasmolytic agents |
| 03/15/2006 | EP1633403A2 Codrugs of diclofenac |
| 03/15/2006 | EP1633402A2 Pharmaceutical composition |
| 03/15/2006 | EP1633401A1 A pharmaceutical composition comprising a p2x7-receptor antagonist and a tumour necrosis factor alpha |
| 03/15/2006 | EP1633400A2 Therapeutic combinations of atypical antipsychotics with gaba modulators, anticonvulsants or benzodiazapines |
| 03/15/2006 | EP1633394A1 Combined pharmaceutical preparations for the treatment of cancer, containing glutaminase and antineoplastic anthracyclines or platinum compounds |
| 03/15/2006 | EP1633379A1 Composition comprising bamboo extract and the compounds isolated therefrom showing treating and preventing activity for inflammatory and blood circulation disease |
| 03/15/2006 | EP1633377A1 A method of treating or preventing chronic wounds and a complete nutritional composition comprising glycine and/or leucine for use therein |
| 03/15/2006 | EP1633376A1 Compositions for prevention and treatment of cold and influenza-like symptoms comprising chelated zinc |
| 03/15/2006 | EP1633375A1 Combination consisting of a magnesium preparation having a prolonged release and of another active substance, and use thereof in the fields of cosmetics, therapeutics and/or nutrition |
| 03/15/2006 | EP1633374A1 Composition consisting of alkane dicarboxylic acids and a pharmaceutically active ingredient |
| 03/15/2006 | EP1633373A1 Pharmaceutical composition comprising glucan derived from microalgae |
| 03/15/2006 | EP1633372A2 Vaccines, immunotherapeutics and methods for using the same |
| 03/15/2006 | EP1633371A1 Method of treating atrial fibrillation or atrial flutter |
| 03/15/2006 | EP1633370A2 Combination of an aldosterone receptor antagonist and an anti-obesity agent |
| 03/15/2006 | EP1633369A1 Process to minimize loss through adhesion to equipment surfaces |
| 03/15/2006 | EP1633367A2 Antiangiogenic agents |
| 03/15/2006 | EP1633366A1 Pharmaceutical composition based on agonist of benzodiazepine |
| 03/15/2006 | EP1633365A1 Macrocyclic quinazoline derivatives as antiproliferative agents |
| 03/15/2006 | EP1633364A2 Methods for the production of sildenafil base and citrate salt |
| 03/15/2006 | EP1633363A1 Pyridinyl acetonitriles |
| 03/15/2006 | EP1633362A2 Compounds, methods and pharmaceutical compositions for inhibiting parp |
| 03/15/2006 | EP1633361A1 Anxiety treatments with ziprasidone |
| 03/15/2006 | EP1633360A1 Treatment of psychotic and depressive disorders |
| 03/15/2006 | EP1633359A1 Use of efletirizine for treating persistent allergic rhinitis |
| 03/15/2006 | EP1633358A1 Pharmaceutical compositions of varenicline |
| 03/15/2006 | EP1633357A1 Polymorphic form of montelukast sodium |
| 03/15/2006 | EP1633356A1 Treatment of tay sachs or sandhoff diseases by enhancing hexosaminidase activity |
| 03/15/2006 | EP1633355A1 Benzothiazole derivatives and use thereof in the treatment of diseases related to the adenosine a2a receptor |